The Latest SPAC News and Rumors: November 15, 2021

Below is a daily summary of links to theca latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Vacasa reports third quarter results and Revelation Biosciences initiates Phase 1b clinical study of REVTx-99

Vacasa Reports Record Third Quarter 2021 Results

Vacasa, North America’s leading vacation rental management platform, today announced financial results for the third quarter ended September 30, 2021.

Gross Booking Value reached $776 million in the third quarter, up 97% year-over-year. As a result, Revenue reached an all-time high of $330 million in the third quarter, up 77% year-over-year and $72 million, or 28%, above the target of $258 million.

In Summer 2021, Vacasa entered into an agreement to become a publicly traded company through a business combination with TPG Pace Solutions (NYSE: TPGS).

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

Revelation Biosciences Inc., a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today the initiation for its Phase 1b proof-of-concept nasal allergen challenge clinical study (RVL-CLR01) to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps.

The study is being conducted in Australia and is enrolling individuals 18 to 55 years of age with a presumed history of allergic rhinitis to rye grass pollen.

Revelation recently announced that it has entered into a definitive merger agreement with Petra Acquisition, Inc. (NASDAQ: PAIC) for a business combination that will result in Revelation becoming a publicly traded company.